Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emvistegrast in Moderately to Severely Active Ulcerative Colitis
NCT06290934Phase 2Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Mar 2024
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 22
01
Overview
A Phase 2 trial of emvistegrast in ulcerative colitis (UC), sponsored by Gilead Sciences. Started Mar 2024; status: active, not recruiting.
02
Drugs
emvistegrast
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06290934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06290934.